Albert Bourla, Pfizer CEO (Matthew Busch/Bloomberg via Getty Images)
Pfizer's migraine nasal spray from Biohaven notches approval
Pfizer’s nabbed its first approval out of its Biohaven acquisition with a nod for migraine spray Zavzpret on Friday. The FDA approval also marks a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
